ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1378

Validity of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Early Spondyloarthritis

Cruz Fernández-Espartero1, Eugenio De Miguel2, Milena Gobbo3, Carmen Martínez4, Miguel A. Descalzo4, Estíbaliz Loza Sr.5 and Esperanza Group6, 1Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain, 2Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 3Research Unit, Spanish Society of Rheumatology., Madrid, Spain, 4Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 5Research Unit. Sociedad Española de Reumatología, Madrid, Spain, 6Madrid

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords:

Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recently, a Working Group of the SpondyloArtrhitis International Society (ASAS) has proposed a composite disease activity score, the Ankylosing Spondylitis Disease Activity Score (ASDAS), for patients with ankylosing spondylitis (AS), for improved and feasible measures of disease activity and treatment response in patients with spondyloarthritis (SpA).

Objective: To evaluate the validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) as clinical tool for measurement of disease activity in early spondyloarthritis (SpA) in comparison with conventional clinical measures of disease activity. To assess the discriminative ability and correlation of the ASDAS and Bath Ankylosing Spondylitis Activity Disease Activity Index (BASDAI) with disease activity in early SpA.

Methods:

Patients with early SpA were selected from ESPeranza database (n=676). To test concurrent validity of the indices, correlations of the two indices with activity variables were calculated in ESPeranza database. Patients were categorised into high and low disease activity states based on patient and physician global assessment scores and physician´s decision to start on a disease-modifying anti-rheumatic drug or tumour necrosis factor blocker. Discriminatory ability of the indices was compared using the approach of standardised mean difference between subgroups of patients with high vs low disease activity.

Results:

ASDAS-B and C showed good correlation with BASDAI (0.79, 0.74, p<0.001). Both scores correlated well with disease activity as reflected by the patient global assessment (BASDAI 0.71, ASDAS-B 0.70, ASDAS-C 0.70, p <0.001) and the physician global score (r=0.44 for BASDAI, r=0.46 for ASDAS-B, r=0.47 for ASDAS-C, p <0.001). CRP and ESR showed poor correlation with patient- and physician-derived disease activity scores. ASDAS and BASDAI scores show good and moderate discriminative ability with different constructs of disease activity.

Conclusion:

ASDAS is a disease activity index valid in early Spa. ASDAS and BASDAI scores show good and moderate discriminative ability and correlation with different constructs of disease activity. In early Spa, ASDAS showed a slight superiority to BASDAI in its ability to discriminate between high and low disease activity states.

Disclosure:

C. Fernández-Espartero,
None;

E. De Miguel,
None;

M. Gobbo,
None;

C. Martínez,
None;

M. A. Descalzo,
None;

E. Loza Sr.,
None;

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validity-of-ankylosing-spondylitis-disease-activity-score-asdas-in-patients-with-early-spondyloarthritis/